Specialty Clinical Research of St. Louis

St Louis, Missouri 63141

6 studies enrolling now · 15 studies all time

What they study most

Bladder Cancer, FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, High-Risk Non-Muscle-Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Incontinence, Urinary, Intermediate Risk Non-Muscle Invasive Bladder Cancer, Low-grade NMIBC, Lower Urinary Tract Symptoms

Studies at this site

• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States — Recruiting now
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer — Recruiting now
• Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC — Recruiting now
• A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) — Recruiting now
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T — Recruiting now
• Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer — Running, not enrolling
• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
• Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin — Running, not enrolling
• A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) — Running, not enrolling
• A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT — Running, not enrolling
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate — Completed
• A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer — Running, not enrolling
• INTIBIA Pivotal Study — Running, not enrolling